WILLOW ANNOUNCES A SECOND PROGRAM WITH GLOBAL INGREDIENT MANUFACTURER TO DEVELOP AN ENZYME FOR MANUFACTURING A LARGE VOLUME ACTIVE PHARMACEUTICAL INGREDIENT
Willow Biosciences (TSX: WLLW; OTCQB: CANSF) has announced a second collaboration with a leading Active Pharmaceutical Ingredient (API) manufacturer. This new program aims to develop an optimized enzyme for large-scale manufacturing of a high-volume API used in a therapeutic with a global market exceeding $1 billion. The development phase is expected to last about six months, with potential milestone payments achievable by 2025. This marks Willow's 4th commercial agreement this year with potential milestone payments as early as next year. The collaboration builds on the success of their first program announced in January 2024, where Willow has already met certain development goals.
Willow Biosciences (TSX: WLLW; OTCQB: CANSF) ha annunciato una seconda collaborazione con un importante produttore di Principi Attivi Farmaceutici (API). Questo nuovo programma mira a sviluppare un enzima ottimizzato per la produzione su larga scala di un API ad alto volume utilizzato in una terapia con un mercato globale che supera 1 miliardo di dollari. La fase di sviluppo dovrebbe durare circa sei mesi, con potenziali pagamenti di milestone raggiungibili entro il 2025. Questo segna il 4° accordo commerciale di Willow quest'anno, con potenziali pagamenti di milestone già il prossimo anno. La collaborazione si basa sul successo del loro primo programma annunciato nel gennaio 2024, dove Willow ha già raggiunto determinati obiettivi di sviluppo.
Willow Biosciences (TSX: WLLW; OTCQB: CANSF) ha anunciado una segunda colaboración con un importante fabricante de Ingredientes Farmacéuticos Activos (API). Este nuevo programa tiene como objetivo desarrollar una enzima optimizada para la fabricación a gran escala de un API de alto volumen utilizado en una terapia con un mercado global que supera los 1 mil millones de dólares. Se espera que la fase de desarrollo dure aproximadamente seis meses, con posibles pagos por hitos alcanzables para 2025. Esto marca el 4° acuerdo comercial de Willow este año, con pagos de hitos potenciales tan pronto como el próximo año. La colaboración se basa en el éxito de su primer programa anunciado en enero de 2024, donde Willow ya ha cumplido con ciertos objetivos de desarrollo.
Willow Biosciences (TSX: WLLW; OTCQB: CANSF)는 주요 의약품 원료(API) 제조업체와의 두 번째 협력을 발표했습니다. 이 새로운 프로그램은 대규모 생산을 위한 최적화된 효소 개발을 목표로 하며, 10억 달러를 초과하는 글로벌 시장에서 사용되는 대량 API의 생산에 초점을 맞추고 있습니다. 개발 단계는 약 6개월 정도 소요될 것으로 예상되며, 2025년까지 달성 가능한 이정표에 대한 잠재적 지불이 있습니다. 이는 Willow가 올해 체결한 4번째 상업적 계약으로, 내년에도 잠재적인 이정표 지급이 가능할 수 있습니다. 이 협력은 2024년 1월에 발표된 첫 번째 프로그램의 성공을 바탕으로 하고 있으며, Willow는 이미 특정 개발 목표를 달성했습니다.
Willow Biosciences (TSX: WLLW; OTCQB: CANSF) a annoncé une deuxième collaboration avec un acteur majeur de la fabrication de Principes Actifs Pharmaceutiques (API). Ce nouveau programme vise à dévvelopper une enzyme optimisée pour la fabrication à grande échelle d'un API à fort volume utilisé dans une thérapie ayant un marché mondial dépassant 1 milliard de dollars. La phase de développement devrait durer environ six mois, avec des paiements d'étapes potentiels réalisables d'ici 2025. Cela marque le 4ème accord commercial de Willow cette année, avec des paiements d'étapes potentiels dès l'année prochaine. La collaboration s'appuie sur le succès de leur premier programme annoncé en janvier 2024, où Willow a déjà atteint certains objectifs de développement.
Willow Biosciences (TSX: WLLW; OTCQB: CANSF) hat eine zweite Zusammenarbeit mit einem führenden Hersteller von Wirkstoffen (API) bekannt gegeben. Dieses neue Programm zielt darauf ab, ein optimiertes Enzym für die Großproduktion eines hochvolumigen API zu entwickeln, das in einer Therapie mit einem globalen Markt von über 1 Milliarde Dollar verwendet wird. Die Entwicklungsphase wird voraussichtlich etwa sechs Monate dauern, mit möglichen Meilensteinzahlungen, die bis 2025 erreicht werden können. Dies markiert Willow's 4. Handelsvereinbarung in diesem Jahr, mit möglichen Meilensteinzahlungen bereits im nächsten Jahr. Die Zusammenarbeit baut auf dem Erfolg ihres ersten Programms auf, das im Januar 2024 angekündigt wurde, wo Willow bereits bestimmte Entwicklungsziele erreicht hat.
- Second collaboration with a leading API manufacturer, indicating strong business relationships
- Development of enzyme for large-volume API with global market exceeding $1 billion
- Potential milestone payments achievable by 2025
- Fourth commercial agreement this year with potential near-term payments
- Successful achievement of development goals in the first program
- None.
Rapid success of first program leads to second collaboration to develop optimized enzyme for large scale manufacturing process
Enzyme development expected to enable commercial-scale production of the API in 2025
Willow's collaboration partner, who currently sells the target API, has now sought Willow's expertise to develop an enzyme to replace an existing complex large scale chemical process. The development phase of this funded collaboration is expected to last approximately six months with additional milestone payments to be made for achieving defined performance targets, which could be achieved as early as 2025. This API partnership represents Willow's 4th announced commercial agreement year to date that contains milestone or other commercial payments that could be received as early as next year.
"We are excited to start a second program with this leading API manufacturer to apply our technology platform to the production of more sustainable APIs for existing, large volume global markets," said Dr. Chris Savile, Willow's President & CEO. "The ultimate goal of any successful business is to establish a long-term relationship with its partners." continued Dr. Savile.
About Willow Biosciences Inc.
Willow develops and produces precision fermented functional ingredients for the health and wellness, food and beverage and personal care markets. Willow's FutureGrown™ and BioOxi™ platforms enable large-scale production with sustainability at its core. Willow's R&D team has a proven track record of developing and commercializing bio-based manufacturing processes and products to benefit our B2B partners and their customers. For more information, visit www.willowbio.com.
FutureGrown™ and BioOxi™ are registered trademarks of Willow Biosciences Inc. All other trademarks are trademarks of their respective holders.
Forward-Looking Statements
This news release may include forward-looking statements including opinions, assumptions, estimates and the Company's assessment of future plans and operations, and, more particularly, statements concerning: the development programs with its biopharma partner, including the ability to accommodate new programs and to expand capabilities;; the demand and market size potential of the synthetic ingredients industry; and the business plan of the Company, generally, including becoming a leader in precision fermentation, research and production of functional ingredients. When used in this news release, the words "will," "anticipate," "believe," "estimate," "expect," "intent," "may," "project," "should," "could," and similar expressions are intended to be among the statements that identify forward-looking statements. The forward-looking statements are founded on the basis of expectations and assumptions made by the Company which include, but are not limited to: the success of Willow's strategic partnerships, including the development of future strategic partnerships; the financial strength of the Company; the ability of the Company to fund its business plan using cash on hand and existing resources; the market for Willow's products; the ability of the Company to obtain and retain applicable licences; the ability of the Company to obtain suitable manufacturing partners and other strategic relationships; and the successful implementation of Willow's commercialization and production strategy, generally. Forward-looking statements are subject to a wide range of risks and uncertainties, and although the Company believes that the expectations represented by such forward-looking statements are reasonable, there can be no assurance that such expectations will be realized. Any number of important factors could cause actual results biotechnology industry in general; the success of the Company's research and development strategies; infringement on intellectual property; failure to benefit from partnerships or successfully integrate acquisitions; actions and initiatives of federal and provincial governments and changes to government policies and the execution and impact of these actions, initiatives and policies; competition from other industry participants; adverse
The forward-looking statements contained in this news release are made as of the date hereof and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, except as required by applicable law. The forward-looking statements contained herein are expressly qualified by this cautionary statement.
View original content to download multimedia:https://www.prnewswire.com/news-releases/willow-announces-a-second-program-with-global-ingredient-manufacturer-to-develop-an-enzyme-for-manufacturing-a-large-volume-active-pharmaceutical-ingredient-302252430.html
SOURCE Willow Biosciences Inc.
FAQ
What is the purpose of Willow Biosciences' second program with the API manufacturer?
When does Willow Biosciences (CANSF) expect to complete the development phase of the new collaboration?
How many commercial agreements has Willow Biosciences announced in 2024?
What is the potential market size for the therapeutic associated with the API in Willow's new collaboration?
